Y. Sezgin, İbrahim Aydın, Abdurrahman Bicer, Alper Can
Aims: In the Eastern Anatolia Region of Turkey it is estimated that the gastric cancer is seen more frequently compared to other regions. As is well known, a reduction in the incidence of certain cancers with high vitamin D value was identified, and vitamin D has been shown to have positive effects on the prognosis of these diseases. In our study, we aimed to investigate the relationship between vitamin D values before treatment and prognosis in patients with gastric cancer. Methods: This study includes 76 patients who had diagnosis of gastric cancer for the first time and admitted to Oncology Clinic in Van Yuzuncu Yil University Faculty of Medicine (YYU) Hospital. Patients inclusion criterias have been identified as lack of story for recently blood transfusion, treatment with any medication and being taken any mineral supplements. Patients vitamin D and tumor markers values were measured at diagnosis. Vitamin D values at diagnosis and stage of the disease, 6. 12. month mortality and disease progression were compared. Results: A total of 76 patients were included in the study. Mean value of vitamin D was 16.1 (3-27). There was not a significant correlation between vitamin D value and stage of disease. Mean age was 60(33-89). Of the patients 26 (34.2 percent) had no metastasis, 15 (19.2 percent) had only liver metastasis, 8(10.5 percent) had only lung metastasis and 27(35.5 percent) had two or more region metastasis. Conclusion: In our study, vitamin D deficiency was present in all gastric cancer patients regardless of stage, indicating that vitamin D deficiency is a poor risk factor in gastric cancer.
目的：据估计，土耳其东安纳托利亚地区的胃癌发病率高于其他地区。众所周知，维生素 D 值越高，某些癌症的发病率就越低，而且维生素 D 对这些疾病的预后也有积极影响。在我们的研究中，我们旨在调查胃癌患者治疗前维生素 D 值与预后之间的关系。研究方法本研究包括 76 名首次确诊胃癌并在凡尔运库尔大学医学院（YYU）医院肿瘤诊所住院的患者。纳入患者的标准是近期没有输血记录、没有接受任何药物治疗、没有服用任何矿物质补充剂。在诊断时测量患者的维生素 D 和肿瘤标志物值。将诊断时的维生素 D 值与疾病分期、6 个月至 12 个月的死亡率和疾病进展情况进行比较：结果：共有 76 名患者被纳入研究。维生素 D 的平均值为 16.1（3-27）。维生素 D 值与疾病阶段无明显相关性。平均年龄为 60 岁（33-89 岁）。26例（34.2%）患者没有转移灶，15例（19.2%）仅有肝转移灶，8例（10.5%）仅有肺转移灶，27例（35.5%）有两个或两个以上区域的转移灶。结论在我们的研究中，所有胃癌患者无论处于哪个阶段都存在维生素 D 缺乏症，这表明维生素 D 缺乏症是胃癌的一个不良危险因素。
{"title":"Effect of vitamin D on prognosis in patients with gastric cancer","authors":"Y. Sezgin, İbrahim Aydın, Abdurrahman Bicer, Alper Can","doi":"10.51271/jchor-0026","DOIUrl":"https://doi.org/10.51271/jchor-0026","url":null,"abstract":"Aims: In the Eastern Anatolia Region of Turkey it is estimated that the gastric cancer is seen more frequently compared to other regions. As is well known, a reduction in the incidence of certain cancers with high vitamin D value was identified, and vitamin D has been shown to have positive effects on the prognosis of these diseases. In our study, we aimed to investigate the relationship between vitamin D values before treatment and prognosis in patients with gastric cancer. \u0000Methods: This study includes 76 patients who had diagnosis of gastric cancer for the first time and admitted to Oncology Clinic in Van Yuzuncu Yil University Faculty of Medicine (YYU) Hospital. Patients inclusion criterias have been identified as lack of story for recently blood transfusion, treatment with any medication and being taken any mineral supplements. Patients vitamin D and tumor markers values were measured at diagnosis. Vitamin D values at diagnosis and stage of the disease, 6. 12. month mortality and disease progression were compared.\u0000Results: A total of 76 patients were included in the study. Mean value of vitamin D was 16.1 (3-27). There was not a significant correlation between vitamin D value and stage of disease. Mean age was 60(33-89). Of the patients 26 (34.2 percent) had no metastasis, 15 (19.2 percent) had only liver metastasis, 8(10.5 percent) had only lung metastasis and 27(35.5 percent) had two or more region metastasis. \u0000Conclusion: In our study, vitamin D deficiency was present in all gastric cancer patients regardless of stage, indicating that vitamin D deficiency is a poor risk factor in gastric cancer.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"493 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140458500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acute myeloid leukaemia (AML) is a heterogeneous disease including cytogenetic and molecular abnormalities. Age, performance status and specific genetic characteristics are important in prognosis. Both directing consolidation treatment and having genetic-based treatment targets have made genetic results even more important. The European LeukemiaNet (ELN) 2022 report was published by expanding the genetic mutation profile. In order to question what this update has changed in clinical practice, we reviewed the data of patients with acute myeloid leukaemia in whom myeloid panel was studied by Next-Generation Sequencing (NGS).
{"title":"Contributions of ELN2022 update and new genetic analysis tests in the risk assesment and treatment of acute myeloid leukaemia","authors":"Seda Yilmaz, M. Bağcı, Abdulkadir Baştürk","doi":"10.51271/jchor-0031","DOIUrl":"https://doi.org/10.51271/jchor-0031","url":null,"abstract":"Acute myeloid leukaemia (AML) is a heterogeneous disease including cytogenetic and molecular abnormalities. Age, performance status and specific genetic characteristics are important in prognosis. Both directing consolidation treatment and having genetic-based treatment targets have made genetic results even more important. The European LeukemiaNet (ELN) 2022 report was published by expanding the genetic mutation profile. In order to question what this update has changed in clinical practice, we reviewed the data of patients with acute myeloid leukaemia in whom myeloid panel was studied by Next-Generation Sequencing (NGS).","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"159 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140458938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aims: Mean platelet volume (MPV) is a measurement based on platelet morphology. We aimed to investigate whether MPV and platelet count exhibit a daily change in relation to the days and gender. Methods: Healthy blood donors aged 18–55 years with no history of the disease and/or drug use participated in the study. MPV values and platelet counts were analyzed with respect to the date of the blood test and the gender of the participant based on a 29–day calendar. Results: A total of 14718 participants (7772 female) were included. The median age of the females and males was similar (38 [range 18–54], and 36 [18–55], p=0.254, respectively). Median platelet count was 278 × 109/L (range 152–448) in females and 244 × 109/L (range 151–439) in males, with a significant difference (p<0.01). The median MPV was 8.9 (range 5.7–12.2) fL in females and 8.4 (range 5.9–12.8) fl in males (p<0.01). MPV and platelet counts were higher in females on all days of the month compared to males. Decreases in MPV values were observed in both females and males on days 9th, 12th, 20th, and 26th, whereas increases in both occurred on days 5th, 15th, 23rd, and 29th. Conclusion: We demonstrated that MPV and platelet count exhibited a daily fluctuating in healthy individuals; MPV values and platelet count were overall higher in females. This study may give a different perspective on future studies of MPV and a lead for evaluating daily changes on other blood parameters.
{"title":"Do mean platelet volume and platelet count vary on a daily or gender basis?","authors":"Ömer Candar, Ömer Ekinci, Ali Doğan, S. Ebinç","doi":"10.51271/jchor-0027","DOIUrl":"https://doi.org/10.51271/jchor-0027","url":null,"abstract":"Aims: Mean platelet volume (MPV) is a measurement based on platelet morphology. We aimed to investigate whether MPV and platelet count exhibit a daily change in relation to the days and gender.\u0000Methods: Healthy blood donors aged 18–55 years with no history of the disease and/or drug use participated in the study. MPV values and platelet counts were analyzed with respect to the date of the blood test and the gender of the participant based on a 29–day calendar.\u0000Results: A total of 14718 participants (7772 female) were included. The median age of the females and males was similar (38 [range 18–54], and 36 [18–55], p=0.254, respectively). Median platelet count was 278 × 109/L (range 152–448) in females and 244 × 109/L (range 151–439) in males, with a significant difference (p<0.01). The median MPV was 8.9 (range 5.7–12.2) fL in females and 8.4 (range 5.9–12.8) fl in males (p<0.01). MPV and platelet counts were higher in females on all days of the month compared to males. Decreases in MPV values were observed in both females and males on days 9th, 12th, 20th, and 26th, whereas increases in both occurred on days 5th, 15th, 23rd, and 29th.\u0000Conclusion: We demonstrated that MPV and platelet count exhibited a daily fluctuating in healthy individuals; MPV values and platelet count were overall higher in females. This study may give a different perspective on future studies of MPV and a lead for evaluating daily changes on other blood parameters.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"45 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140458030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aims: Chemotherapy remains a cornerstone in treating metastatic gastric cancer (GC), yet the management of elderly patients, who often face distinct challenges, lacks comprehensive guidelines. The aim of this study was to compare the efficacy and side effects of single-agent and double-agent chemotherapy regimens in first-line treatment of elderly patients with HER-2 negative metastatic GC. Methods: We retrospectively evaluated HER-2 negative metastatic GC patients aged 80 years and older who were treated at Van Yüzüncü Yıl University Medical Faculty Dursun Odabaşı Medical Center Oncology Clinic between 2010 and 2023. Demographic characteristics, treatment regimens and responses, prognostic factors, grade 3-4 toxicity, progression-free survival (PFS), and overall survival (OS) were analyzed. Results: The mean age of 56 patients was 82.6 ± 2.3 years and 24 (42.9%) of them were women. Single-agent chemotherapy was administered to 33 (58.9%) patients, while 23 (41.1%) received double-agent chemotherapy. The median OS was 5 months (95% CI, 2.9 to 7.1) in the single-agent group and 10 months (95% CI, 4.2 to 15.8) in the double-agent group (p = 0.237), although there was a numerical difference, it was not statistically significant. Median PFS was longer with double-agent chemotherapy, but not statistically significant (6 months vs. 4 months, p = 0.668). No statistically significant difference was found in the side effect rates of patients receiving single and double-agent chemotherapy. Conclusion: In our study, despite the absence of statistical significance in the survival rates among patients receiving double chemotherapeutic agents, their survival was twice as long as that of individuals receiving a single agent. Furthermore, no significant differences in terms of side effects were observed. These findings suggest that, even in individuals aged 80 years and older, a preference for double-agent chemotherapy should be considered when feasible.
{"title":"Comparison of efficacy and tolerability of single agent and double agent chemotherapy regimens in first-line treatment of elderly patients with her-2 negative metastatic gastric cancer","authors":"Gürkan Güner, Muslih Ürün","doi":"10.51271/jchor-0029","DOIUrl":"https://doi.org/10.51271/jchor-0029","url":null,"abstract":"Aims: Chemotherapy remains a cornerstone in treating metastatic gastric cancer (GC), yet the management of elderly patients, who often face distinct challenges, lacks comprehensive guidelines. The aim of this study was to compare the efficacy and side effects of single-agent and double-agent chemotherapy regimens in first-line treatment of elderly patients with HER-2 negative metastatic GC.\u0000Methods: We retrospectively evaluated HER-2 negative metastatic GC patients aged 80 years and older who were treated at Van Yüzüncü Yıl University Medical Faculty Dursun Odabaşı Medical Center Oncology Clinic between 2010 and 2023. Demographic characteristics, treatment regimens and responses, prognostic factors, grade 3-4 toxicity, progression-free survival (PFS), and overall survival (OS) were analyzed. \u0000Results: The mean age of 56 patients was 82.6 ± 2.3 years and 24 (42.9%) of them were women. Single-agent chemotherapy was administered to 33 (58.9%) patients, while 23 (41.1%) received double-agent chemotherapy. The median OS was 5 months (95% CI, 2.9 to 7.1) in the single-agent group and 10 months (95% CI, 4.2 to 15.8) in the double-agent group (p = 0.237), although there was a numerical difference, it was not statistically significant. Median PFS was longer with double-agent chemotherapy, but not statistically significant (6 months vs. 4 months, p = 0.668). No statistically significant difference was found in the side effect rates of patients receiving single and double-agent chemotherapy.\u0000Conclusion: In our study, despite the absence of statistical significance in the survival rates among patients receiving double chemotherapeutic agents, their survival was twice as long as that of individuals receiving a single agent. Furthermore, no significant differences in terms of side effects were observed. These findings suggest that, even in individuals aged 80 years and older, a preference for double-agent chemotherapy should be considered when feasible.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"10 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140458875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome is a birth defect of the blood vessels that causes telangiectasias and arteriovenous malformations. HHT is a rare, autosomal dominant vascular disorder affecting approximately 1 in 8000 people. This multisystem angiogenic disorder is genetically and phenotypically variable, with the most common symptom being severe and recurrent epistaxis. ALK1, TGF-ß, and VEGF are involved in its pathogenesis. VEGF increases mitotic activity in vascular endothelial cells, leading to uncontrolled angiogenesis and the formation of fragile vessels. Bevacizumab is used in the treatment of HHT by inhibiting VEGF. We present our patient, who developed hepatic encephalopathy due to hemorrhages with diffuse telangiectasias of the skin and tongue due to HHT and achieved an effective response to both conditions with bevacizumab.
{"title":"Get two with one: bevacizumab treatment in hereditary hemorrhagic telangiectasia with concomitant cirrhosis","authors":"Serhat Çelik, L. Kaynar","doi":"10.51271/jchor-0030","DOIUrl":"https://doi.org/10.51271/jchor-0030","url":null,"abstract":"Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome is a birth defect of the blood vessels that causes telangiectasias and arteriovenous malformations. HHT is a rare, autosomal dominant vascular disorder affecting approximately 1 in 8000 people. This multisystem angiogenic disorder is genetically and phenotypically variable, with the most common symptom being severe and recurrent epistaxis. ALK1, TGF-ß, and VEGF are involved in its pathogenesis. VEGF increases mitotic activity in vascular endothelial cells, leading to uncontrolled angiogenesis and the formation of fragile vessels. Bevacizumab is used in the treatment of HHT by inhibiting VEGF. We present our patient, who developed hepatic encephalopathy due to hemorrhages with diffuse telangiectasias of the skin and tongue due to HHT and achieved an effective response to both conditions with bevacizumab.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"298 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140458433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aims: Myelodysplastic syndrome (MDS) is a clonal bone marrow neoplasia characterized by morphological findings of dysplasia in hematopoietic cells, peripheral cytopenia(s), ineffective hematopoiesis, recurrent genetic abnormalities, and an increased risk of conversion to acute myeloid leukemia (AML). The International Prognostic Scoring System (IPSS) is the most commonly used prognostic classification system for MDS. Classification was made by a combination of morphology, cytopenia, and genetic studies. In this study, we aimed to examine the parameters that affect prognosis in MDS patients, show their effects on mortality, and evaluate their positive or negative effects on the course of the disease. Methods: Two hundred twenty-nine patients who applied to Erciyes University Faculty of Medicine, Department of Hematology, and were diagnosed with MDS according to WHO classification between 2010 and 2020 were included in this retrospective study. Age, gender, additional disease status, laboratory parameters, bone marrow biopsy materials, and genetic mutation analysis data were available. The bone marrow aspiration and biopsy examinations of each patient were evaluated and categorized according to the WHO classification. The prognosis was evaluated according to the data of the patients, survival-exitus, and survival after MDS-AML conversion. Risk scoring was analyzed with three different scoring systems (IPSS, WPSS, and R-IPSS). Results: Of the 229 MDS patients included in the study, 57% (131) were male. The mean age of the patients was 67 years. Age, MDS-AML conversion times, disease duration, cellularity, and pathology blast rate were found to be statistically significant between the groups (p<0.05). Leukocyte, neutrophil, platelet, hematocrit, lymphocyte, monocyte, CRP, erythropoietin, ferritin, and LDH data were found to be statistically significant regarding survival (p<0.05). Age, IPSS risk status 3, and W-PSS risk status 3 were found to be independent risk factors affecting survival. Conclusion: Age, IPSS high risk, and WPSS high risk status were found to be independent risk factors affecting survival. Although our study revealed important data in the analysis of MDS patients, single-center analysis of patients and retrospective analysis revealed the need for further studies.
{"title":"Factors affecting prognosis in myelodysplastic syndrome: an 11 years’ experience from a tertiary care center","authors":"Emrullah Doğan, Ekrem Küçükoğlu, M. Keklik","doi":"10.51271/jchor-0028","DOIUrl":"https://doi.org/10.51271/jchor-0028","url":null,"abstract":"Aims: Myelodysplastic syndrome (MDS) is a clonal bone marrow neoplasia characterized by morphological findings of dysplasia in hematopoietic cells, peripheral cytopenia(s), ineffective hematopoiesis, recurrent genetic abnormalities, and an increased risk of conversion to acute myeloid leukemia (AML). The International Prognostic Scoring System (IPSS) is the most commonly used prognostic classification system for MDS. Classification was made by a combination of morphology, cytopenia, and genetic studies. In this study, we aimed to examine the parameters that affect prognosis in MDS patients, show their effects on mortality, and evaluate their positive or negative effects on the course of the disease.\u0000Methods: Two hundred twenty-nine patients who applied to Erciyes University Faculty of Medicine, Department of Hematology, and were diagnosed with MDS according to WHO classification between 2010 and 2020 were included in this retrospective study. Age, gender, additional disease status, laboratory parameters, bone marrow biopsy materials, and genetic mutation analysis data were available. The bone marrow aspiration and biopsy examinations of each patient were evaluated and categorized according to the WHO classification. The prognosis was evaluated according to the data of the patients, survival-exitus, and survival after MDS-AML conversion. Risk scoring was analyzed with three different scoring systems (IPSS, WPSS, and R-IPSS).\u0000Results: Of the 229 MDS patients included in the study, 57% (131) were male. The mean age of the patients was 67 years. Age, MDS-AML conversion times, disease duration, cellularity, and pathology blast rate were found to be statistically significant between the groups (p<0.05). Leukocyte, neutrophil, platelet, hematocrit, lymphocyte, monocyte, CRP, erythropoietin, ferritin, and LDH data were found to be statistically significant regarding survival (p<0.05). Age, IPSS risk status 3, and W-PSS risk status 3 were found to be independent risk factors affecting survival.\u0000Conclusion: Age, IPSS high risk, and WPSS high risk status were found to be independent risk factors affecting survival. Although our study revealed important data in the analysis of MDS patients, single-center analysis of patients and retrospective analysis revealed the need for further studies.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"36 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140458181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bayram Yeşil, S. Kaçar, N. Turhan, H. Gökcan, M. Yüksel, F. Bacaksız, Meral Akdoğan Kayhan
Pancreatic metastases account for 2% of pancreatic malignancies and are rare. Metastases to the pancreas originate from many organ systems in the body but occur more frequently from the lung, breast, kidney, and gastrointestinal tract. It may occur years after the treatment of the primary tumor. Symptoms such as abdominal pain, weight loss, and jaundice are present at presentation, but it can also be detected on radiologic imaging without any symptoms. In this article, we present a case of RCC metastasis to the pancreas detected 16 years after renal cell carcinoma (RCC) treatment that was found to be incidental and detected by EUS FNAB.
胰腺转移占胰腺恶性肿瘤的 2%，非常罕见。胰腺转移瘤来源于身体的许多器官系统，但更常发生于肺、乳腺、肾脏和胃肠道。它可能在原发肿瘤治疗多年后发生。发病时会出现腹痛、体重减轻和黄疸等症状，但也可能在没有任何症状的情况下通过放射影像学检查发现。本文介绍了一例在肾细胞癌（RCC）治疗 16 年后发现的 RCC 转移至胰腺的病例，该病例通过 EUS FNAB 意外发现。
{"title":"Pancreatic metastasis of renal cell carcinoma: case report","authors":"Bayram Yeşil, S. Kaçar, N. Turhan, H. Gökcan, M. Yüksel, F. Bacaksız, Meral Akdoğan Kayhan","doi":"10.51271/jchor-0025","DOIUrl":"https://doi.org/10.51271/jchor-0025","url":null,"abstract":"Pancreatic metastases account for 2% of pancreatic malignancies and are rare. Metastases to the pancreas originate from many organ systems in the body but occur more frequently from the lung, breast, kidney, and gastrointestinal tract. It may occur years after the treatment of the primary tumor. Symptoms such as abdominal pain, weight loss, and jaundice are present at presentation, but it can also be detected on radiologic imaging without any symptoms. In this article, we present a case of RCC metastasis to the pancreas detected 16 years after renal cell carcinoma (RCC) treatment that was found to be incidental and detected by EUS FNAB.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139209054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aims: Thalassemia is an inherited anemia characterized by reduced or absent expression of ?- or ß-globulin genes (1). Transfusion dependent thalassemia (TDT) has an increased risk for serious infections, suggesting that a fundamental defect Methods: The study included 61 patients with TDT between the ages of 18 and 45 who were followed up in the hematology clinic of our tertiary care center between 2018 and 2023. For the determination of mononuclear cell surface markers, peripheral blood was processed according to standard procedures, labeled with monoclonal antibodies specific for CD4, CD8, CD3, CD19, and CD56, and analyzed by cytofluorometric analysis with a FACScan flow cytometer (Sysmex UF 1600). Results: In our study, CD4, CD8, CD3, CD19, and CD56 values, which are lymphocyte markers, were examined to evaluate the immune system of patients diagnosed with TDT, and it was observed that there was no significant correlation between these values and the annual infection frequency and mean ferritin values of the patients. Conclusion : The mean age of the 61 patients included in the study was 24.83±6.02 years, and 33 were female and 28 were male. The mean ferritin value was 3150.88±2553.51 ng/ml, and transferrin saturation was 42.42±14.43. The mean number of transfusions per year was 15.39±1.90, and the mean number of detectable infections per year was 2.85±2.02.
{"title":"The relationship between immunologic system and ferritin levels in patients with transfusion dependent thalassemia: a retrospective single-center study","authors":"C. Selim","doi":"10.51271/jchor-0018","DOIUrl":"https://doi.org/10.51271/jchor-0018","url":null,"abstract":"Aims: Thalassemia is an inherited anemia characterized by reduced or absent expression of ?- or ß-globulin genes (1). Transfusion dependent thalassemia (TDT) has an increased risk for serious infections, suggesting that a fundamental defect Methods: The study included 61 patients with TDT between the ages of 18 and 45 who were followed up in the hematology clinic of our tertiary care center between 2018 and 2023. For the determination of mononuclear cell surface markers, peripheral blood was processed according to standard procedures, labeled with monoclonal antibodies specific for CD4, CD8, CD3, CD19, and CD56, and analyzed by cytofluorometric analysis with a FACScan flow cytometer (Sysmex UF 1600). Results: In our study, CD4, CD8, CD3, CD19, and CD56 values, which are lymphocyte markers, were examined to evaluate the immune system of patients diagnosed with TDT, and it was observed that there was no significant correlation between these values and the annual infection frequency and mean ferritin values of the patients. Conclusion : The mean age of the 61 patients included in the study was 24.83±6.02 years, and 33 were female and 28 were male. The mean ferritin value was 3150.88±2553.51 ng/ml, and transferrin saturation was 42.42±14.43. The mean number of transfusions per year was 15.39±1.90, and the mean number of detectable infections per year was 2.85±2.02.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139208185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aims: Since lung cancer is a disease with a high mortality and morbidity rate, determining its prognosis has a very important place. Studies in the literature have shown that electrolyte disturbance and inflammation may be associated with a poor prognosis in lung cancer, however, further studies are needed on this subject. In this study, it was planned to investigate the role of the sodium and globulin ratio measured at the time of diagnosis in the prognosis prediction of patients with lung cancer diagnosis. Methods: The study was carried out retrospectively from the patient files and hospital records of 165 patients who were followed up with the diagnosis of lung cancer between January 1, 2015 and January 1, 2021 in XXXX University (KKU) Faculty of Medicine, Department of Internal Medicine, and Medical Oncology Department. Patients with achievable sodium, albumin, and total protein values at the time of diagnosis were included in the study. The hemogram parameters of the patients included in the study were creatinine and estimated glomerular filtration rate (eGFR), alanine aminotransferase (ALT) level, albumin level, total protein level and globulin level, C-reactive protein (CRP) level, CEA, and TSH levels. In addition, the sodium/globulin ratio (SGR) and the CRP/albumin ratio (CAR) were evaluated. Results: 87.3% of the patients were male, and 12.7% were female. The mean age at presentation was 62.5 ± 9.1 years. Adenocancer accounts for 46.1% of cancers with 76 patients, squamous cell carcinoma for 41.8% with 69 patients, and small cell carcinoma for 12.1% with 20 patients. 11 (6.7%) of the patients were stage 1, 25 (15.2%) stage 2, 58 (35.2%) stage 3, and 71 (43%) stage 4 patients. 111 (67.3%) of the patients died. The average follow-up time is 16.6 months. In the regression analyzes performed in our study, mortality and sodium/globulin ratio (SGR) and progression-free survival and sodium/globulin ratio (SGR) were found to be unrelated. There was a weak negative correlation between the sodium/globulin ratio (SGR) and the CRP/albumin ratio (CAR). In the multivariate regression analysis, the stage of the disease, diabetes, and CRP level were found to be the independent variables affecting mortality and the stage of the disease affecting progression-free survival. (p<0.001). Conclusion: Independent prognostic factors in patients with lung cancer; stage of disease for mortality, diabetes, and CRP level were found to be stages for progression-free survival. Considering the weak relationship between sodium/globulin ratio (SGR) and CRP/albumin ratio (CAR), SGR can be used as a future biomarker to predict prognosis in cancer patients. Further studies are needed to learn more about the relationship between SGR and lung cancer.
{"title":"The place of initial serum sodium and globulin ratio in the prognosis estimation of patients with lung cancer","authors":"Mehmetemin Yerli, Hatice Keleş, Selim Yalçın","doi":"10.51271/jchor-0020","DOIUrl":"https://doi.org/10.51271/jchor-0020","url":null,"abstract":"Aims: Since lung cancer is a disease with a high mortality and morbidity rate, determining its prognosis has a very important place. Studies in the literature have shown that electrolyte disturbance and inflammation may be associated with a poor prognosis in lung cancer, however, further studies are needed on this subject. In this study, it was planned to investigate the role of the sodium and globulin ratio measured at the time of diagnosis in the prognosis prediction of patients with lung cancer diagnosis. Methods: The study was carried out retrospectively from the patient files and hospital records of 165 patients who were followed up with the diagnosis of lung cancer between January 1, 2015 and January 1, 2021 in XXXX University (KKU) Faculty of Medicine, Department of Internal Medicine, and Medical Oncology Department. Patients with achievable sodium, albumin, and total protein values at the time of diagnosis were included in the study. The hemogram parameters of the patients included in the study were creatinine and estimated glomerular filtration rate (eGFR), alanine aminotransferase (ALT) level, albumin level, total protein level and globulin level, C-reactive protein (CRP) level, CEA, and TSH levels. In addition, the sodium/globulin ratio (SGR) and the CRP/albumin ratio (CAR) were evaluated. Results: 87.3% of the patients were male, and 12.7% were female. The mean age at presentation was 62.5 ± 9.1 years. Adenocancer accounts for 46.1% of cancers with 76 patients, squamous cell carcinoma for 41.8% with 69 patients, and small cell carcinoma for 12.1% with 20 patients. 11 (6.7%) of the patients were stage 1, 25 (15.2%) stage 2, 58 (35.2%) stage 3, and 71 (43%) stage 4 patients. 111 (67.3%) of the patients died. The average follow-up time is 16.6 months. In the regression analyzes performed in our study, mortality and sodium/globulin ratio (SGR) and progression-free survival and sodium/globulin ratio (SGR) were found to be unrelated. There was a weak negative correlation between the sodium/globulin ratio (SGR) and the CRP/albumin ratio (CAR). In the multivariate regression analysis, the stage of the disease, diabetes, and CRP level were found to be the independent variables affecting mortality and the stage of the disease affecting progression-free survival. (p<0.001). Conclusion: Independent prognostic factors in patients with lung cancer; stage of disease for mortality, diabetes, and CRP level were found to be stages for progression-free survival. Considering the weak relationship between sodium/globulin ratio (SGR) and CRP/albumin ratio (CAR), SGR can be used as a future biomarker to predict prognosis in cancer patients. Further studies are needed to learn more about the relationship between SGR and lung cancer.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"823 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139202985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Abedi, Serhat Çelik, Zeynep Dilan Özçelik Yılmaz, Z. Güven, L. Kaynar
Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare disease characterized by high serum ferritin levels, congenital bilateral cataracts, and the absence of tissue iron overload. HHCS is a rare disease characterized by high serum ferritin levels, congenital bilateral cataracts, and the absence of tissue iron overload. In this case report, we aimed to present a young female patient with a history of cataracts in herself and her family members. Our patient had the dilemma of iron deficiency anemia and hyperferritinemia. As in our patient, patients with HHCS apply to many outpatient clinics and have difficulty in diagnosis. For this reason, we prepared our case to raise awareness.
{"title":"Hereditary hyperferritinemia cataract syndrome with iron deficiency : a case report","authors":"A. Abedi, Serhat Çelik, Zeynep Dilan Özçelik Yılmaz, Z. Güven, L. Kaynar","doi":"10.51271/jchor-0024","DOIUrl":"https://doi.org/10.51271/jchor-0024","url":null,"abstract":"Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare disease characterized by high serum ferritin levels, congenital bilateral cataracts, and the absence of tissue iron overload. HHCS is a rare disease characterized by high serum ferritin levels, congenital bilateral cataracts, and the absence of tissue iron overload. In this case report, we aimed to present a young female patient with a history of cataracts in herself and her family members. Our patient had the dilemma of iron deficiency anemia and hyperferritinemia. As in our patient, patients with HHCS apply to many outpatient clinics and have difficulty in diagnosis. For this reason, we prepared our case to raise awareness.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"819 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139202989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：